Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $54 from $74 and keeps a Buy rating on the shares. The target reduction comes following its update from its ongoing Ph3 studies. The main takeaway is that things are *mostly* on track. Newly updated / slightly delayed is progress with the MAGNITUDE study of nex-z for ATTR-CM – the company has enrolled about 48% of the target number of patients so far though now plans to complete enrollment by early 2027 versus YE26 previously.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
- Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
- Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
- Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
- Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue